A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT ID: NCT06838273

Last Updated: 2025-09-24

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 720 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-02-24
• Study Completion Date: 2028-12-31

Brief Summary

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.

Conditions

Non-small Cell Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BL-B01D1 in Combination with Osimertinib

Participants receive BL-B01D1 in Combination with Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

BL-B01D1

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

Osimertinib

Intervention Type: DRUG

Oral administration, 80mg daily for a cycle of 3 weeks.

Osimertinib

Participants receive Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: ACTIVE_COMPARATOR

Osimertinib

Intervention Type: DRUG

Oral administration, 80mg daily for a cycle of 3 weeks.

Interventions

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

Osimertinib

Oral administration, 80mg daily for a cycle of 3 weeks.

Intervention Type: DRUG

Osimertinib

Oral administration, 80mg daily for a cycle of 3 weeks.

Intervention Type: DRUG

Other Intervention Names

iza-bren; izalontamab brengitecan; BMS-986507

Eligibility Criteria

Inclusion Criteria

1. Sign the informed consent form voluntarily and follow the protocol requirements;

2. Age ≥18 years old;

3. Expected survival time ≥3 months;

4. Patients with unresectable or radical radiotherapy for locally advanced non-small cell lung cancer;

5. Documentation of EGFR sensitive mutations detected from tumor tissue or blood samples;

6. Consent to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions at or after diagnosis for testing, including EGFR mutation type;

7. At least one measurable lesion meeting the RECIST v1.1 definition was required;

8. ECOG 0 or 1;

9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

11. The organ function level must meet the requirements on the premise that blood transfusion and colony-stimulating factor are not allowed within 14 days before the screening period;

12. Urinary protein ≤2+ or < 1000mg/24h;

13. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria

1. Previous histologic or cytological evidence of small cell or mixed small/non-small cell components;

2. Patients with previous systemic therapy;

3. Patients had received EGFR-TKI therapy;

4. Studies received radical radiotherapy, major surgery, and large area radiotherapy within 4 weeks before randomization;

5. History of severe heart disease and cerebrovascular disease;

6. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;

7. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;

8. Were diagnosed with active malignancy within 3 years before randomization;

9. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure &gt; 150 mmHg or diastolic blood pressure &gt; 100 mmHg);

10. Patients with poor glycemic control;

11. A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis, or a suspicion of such disease;

12. Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;

13. Patients with active central nervous system metastasis;

14. Had a severe infection within 4 weeks before randomization;

15. Patients with massive or symptomatic effusions or poorly controlled effusions;

16. Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;

17. Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;

18. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;

19. Patients with a history of inflammatory bowel disease, extensive bowel resection, immune enteritis, intestinal obstruction or chronic diarrhea;

20. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;

21. Had autologous or allogeneic stem cell transplantation history;

22. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;

23. A history of severe neurological or psychiatric illness;

24. Received other unmarketed investigational drugs or treatments within 4 weeks before randomization;

25. Subjects scheduled for vaccination or who received live vaccine within 28 days before study randomization;

26. Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Sa Xiao, PHD

Role: CONTACT

xiaosa@baili-pharm.com

15013238943

Facility Contacts

Caicun Zhou

Role: primary

Other Identifiers

BL-B01D1-308

Identifier Type: -

Identifier Source: org_study_id